ARK Genomic Revolution ETF vs Ferrari NV — how do they compare? ARK Genomic Revolution ETF trades at $44.51, while Ferrari NV trades at $405.6 (market cap $71.67B). The key difference: Ferrari NV pays a 1.04% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Ferrari NV nearer its low. Which is the better fit depends on your goals.
| ARKG | RACE | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.55 | $504.09 |
52-Week Low | $24.02 | $314.63 |
Market Cap | — | $71.67B |
Enterprise Value | — | $73.60B |
Dividend Yield | — | 1.04% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ferrari (RACE) trades at $407.76, up 0.24% today, near its pivot point of $407 with bullish technical indicators. The stock shows strong fundamentals with a 22.25% net margin and consistent earnings beats, including Q2 2026 EPS of $2.99 versus $2.83 expected. Revenue growth is steady, reaching $7.15B in 2025, supported by high demand and personalization revenue.
Outlook remains positive with a consensus price target of $462.67, though elevated P/E of 37.93 poses valuation risk. Key opportunities include pricing power and EV expansion, while risks involve economic sensitivity and execution on new models. Analyst sentiment is strongly bullish with 72% buy ratings.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →